Apnimed Publishes Restated Quarterly Financial Report

• Apnimed restated second-quarter and first-half 2026 results on November 13, reclassifying a $85.38 million SASS disposal gain from continuing to discontinued operations.
• Second-quarter continuing-operations net income fell to $40.73 million from $126.11 million.
• First-half continuing-operations net income declined to $111.11 million from $196.49 million.
• Total net income remained unchanged at $125.94 million for the quarter; first-half net income stayed at $193.65 million.
• The correction stemmed from a previously disclosed internal control material weakness involving insufficient accounting personnel for complex transactions; cash flows were unaffected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-460871), on November 13, 2026, and is solely responsible for the information contained therein.